TickerFacts.

Aligos Therapeutics, Inc. (ALGS): EPS (Diluted)

Annual figures by period end, from SEC filings.

Stock splits: 1-for-25, first reflected in a filing dated 2024-11-06. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

-$2.45
Year ended 2025-12-31
2022-12-31: -$2.252023-12-31: -$34.202024-12-31: -$20.942025-12-31: -$2.45-$2.45
2022-12-31 EPS (Diluted) (USD per share) 2025-12-31

Paler bars were last filed before a stock split, on the old share basis.

Period endedEPS (Diluted)Change YoYSource filing
2025-12-31-$2.45n/m2026-03-05, From 2025-01-01
2024-12-31-$20.94n/m2026-03-05, From 2024-01-01
2023-12-31-$34.20n/c2025-03-10, From 2023-01-01
2022-12-31-$2.25n/a2024-03-12, From 2022-01-01

EPS (Diluted) at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEPS (Diluted)Change YoY
Aligos Therapeutics, Inc. (ALGS)2025-12-31-$2.45n/m
Humacyte, Inc. (HUMA)2025-12-31-$0.26n/m
Dyadic International Inc (DYAI)2025-12-31-$0.23n/m
Outlook Therapeutics, Inc. (OTLK)2025-09-30-$1.79n/m
Surrozen, Inc. (SRZN)2025-12-31-$32.37n/m
CRISPR Therapeutics AG (CRSP)2025-12-31-$6.47n/m
Inhibrx Biosciences, Inc. (INBX)2025-12-31-$9.04n/m
CG Oncology, Inc. (CGON)2025-12-31-$2.08n/m
Prime Medicine, Inc. (PRME)2025-12-31-$1.35n/m

Compare ALGS, HUMA, DYAI, OTLK side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗